

DAFTAR PUSTAKA

- (1) Wu, F.; Yang, J.; Liu, J.; Wang, Y.; Mu, J.; Zeng, Q.; Deng, S.; Zhou, H. Signaling Pathways in Cancer-Associated Fibroblasts and Targeted Therapy for Cancer. *Signal Transduction and Targeted Therapy*. Springer Nature December 1, 2021. <https://doi.org/10.1038/s41392-021-00641-0>.
- (2) Momenimovahed, Z.; Salehiniya, H. Epidemiological Characteristics of and Risk Factors for Breast Cancer in the World. *Breast Cancer: Targets and Therapy*. Dove Medical Press Ltd. 2019, pp 151–164. <https://doi.org/10.2147/BCTT.S176070>.
- (3) Li, Y.; Zhan, Z.; Yin, X.; Fu, S.; Deng, X. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer. *Frontiers in Oncology*. Frontiers Media S.A. October 28, 2021. <https://doi.org/10.3389/fonc.2021.731535>.
- (4) Medina, M. A.; Oza, G.; Sharma, A.; Arriaga, L. G.; Hernández, J. M. H.; Rotello, V. M.; Ramirez, J. T. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. *International Journal of Environmental Research and Public Health*. MDPI AG March 1, 2020. <https://doi.org/10.3390/ijerph17062078>.
- (5) Li, Y.; Zhang, H.; Merkher, Y.; Chen, L.; Liu, N.; Leonov, S.; Chen, Y. Recent Advances in Therapeutic Strategies for Triple-Negative Breast Cancer. *Journal of Hematology and Oncology*. BioMed Central Ltd December 1, 2022. <https://doi.org/10.1186/s13045-022-01341-0>.
- (6) Lee, Y. T.; Tan, Y. J.; Oon, C. E. Molecular Targeted Therapy: Treating Cancer with Specificity. *European Journal of Pharmacology*. Elsevier B.V. September 5, 2018, pp 188–196. <https://doi.org/10.1016/j.ejphar.2018.07.034>.
- (7) Tripathi, A.; Misra, K. *Molecular Docking: A Structure-Based Drug Designing Approach Finding a Herbal Drug for Parkinson's Disease View Project Designing of Novel Insecticide as Inhibitor against Apple Moth View Project*, 2017. <https://www.researchgate.net/publication/317253042>.
- (8) Yuriev, E.; Ramsland, P. A. Latest Developments in Molecular Docking: 2010–2011 in Review. *Journal of Molecular Recognition* **2013**, 26 (5), 215–239. <https://doi.org/https://doi.org/10.1002/jmr.2266>.

- (9) Susanti, N. M. P.; Damayanti, S.; Kartasasmita, R. E.; Tjahjono, D. H. A Search for Cyclin-Dependent Kinase 4/6 Inhibitors by Pharmacophore-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations. *Int J Mol Sci* **2021**, *22* (24). <https://doi.org/10.3390/ijms222413423>.
- (10) Eliaa, S. G.; Al-Karmalawy, A. A.; Saleh, R. M.; Elshal, M. F. Empagliflozin and Doxorubicin Synergistically Inhibit the Survival of Triple-Negative Breast Cancer Cells via Interfering with the MTOR Pathway and Inhibition of Calmodulin: In Vitro and Molecular Docking Studies. *ACS Pharmacol Transl Sci* **2020**, *3* (6), 1330–1338. <https://doi.org/10.1021/acsptsci.0c00144>.
- (11) McAlpine, J. B.; Bachmann, B. O.; Pirae, M.; Tremblay, S.; Alarco, A.-M.; Zazopoulos, E.; Farnet, C. M. Microbial Genomics as a Guide to Drug Discovery and Structural Elucidation: ECO-02301, a Novel Antifungal Agent, as an Example. *J Nat Prod* **2005**, *68* (4), 493–496. <https://doi.org/10.1021/np0401664>.
- (12) Qadri, M.; Johri, S.; Shah, B. A.; Khajuria, A.; Sidiq, T.; Lattoo, S. K.; Abdin, M. Z.; Riyaz-Ul-Hassan, S. Identification and Bioactive Potential of Endophytic Fungi Isolated from Selected Plants of the Western Himalayas. *Springerplus* **2013**, *2* (1), 8. <https://doi.org/10.1186/2193-1801-2-8>.
- (13) Hardani, I.; Damara, F.; Nugrahani, A.; Bashari, M. Ethanol Extract of *Stylissa Carteri* Induces Cell Death in Parental and Paclitaxel-Resistant Cervical Cancer Cells. *International Journal of Integrated Health Sciences* **2018**, *6*, 91–96. <https://doi.org/10.15850/ijjhs.v6n2.1378>.
- (14) Daffa, D. M.; Bashari, M. H.; Ariyanto, E. F.; Putri, T.; Qomarilla, N. Anti-Migration Effect of *Aptos Suberitoides* Fraction in HCT-116 Colorectal Cancer Cell Line. *Althea Medical Journal* **2021**, *8* (1). <https://doi.org/10.15850/amj.v8n1.2231>.
- (15) Bashari, M. H.; Huda, F.; Tartila, T. S.; Shabrina, S.; Putri, T.; Qomarilla, N.; Atmaja, H.; Subhan, B.; Sudji, I. R.; Meiyanto, E. Bioactive Compounds in the Ethanol Extract of Marine Sponge *Stylissa Carteri* Demonstrates Potential Anti-Cancer Activity in Breast Cancer Cells. *Asian Pac J Cancer Prev* **2019**, *20* (4), 1199–1206. <https://doi.org/10.31557/APJCP.2019.20.4.1199>.
- (16) Farooq, S.; Qayum, A.; Nalli, Y.; Lauro, G.; Chini, M. G.; Bifulco, G.; Chaubey, A.; Singh, S. K.; Riyaz-Ul-Hassan, S.; Ali, A. Discovery of a Secalonic Acid Derivative from *Aspergillus Aculeatus*, an Endophyte of *Rosa Damascena* Mill., Triggers

- Apoptosis in MDA-MB-231 Triple Negative Breast Cancer Cells. *ACS Omega* **2020**, 5 (38), 24296–24310. <https://doi.org/10.1021/acsomega.0c02505>.
- (17) Bashari, M. H.; Subhan Beginer; Elfahmi; Syafrizayanti; Andriani Yosie. Anticancer Effect of Secondary Metabolite Compounds of Fungal Symbionts of Sea Sponge on Breast Cancer Cells : Invitro Study. *Marine Drug (Inpress)* **2022**.
- (18) Shi, J.-H.; Liu, F.; Song, Y. Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer. *Cancer Manag Res* **2020**, 12, 9375–9387.
- (19) Bauer, K. R.; Brown, M.; Cress, R. D.; Parise, C. A.; Caggiano, V. Descriptive Analysis of Estrogen Receptor (ER)-Negative, Progesterone Receptor (PR)-Negative, and HER2-Negative Invasive Breast Cancer, the so-Called Triple-Negative Phenotype. *Cancer* **2007**, 109 (9), 1721–1728. <https://doi.org/https://doi.org/10.1002/cncr.22618>.
- (20) Delaloge, S.; Ezzalfani, M.; Dieras, V.; Bachelot, T. D.; Debled, M.; Jacot, W.; Brain, E.; Mouret-Reynier, M.-A.; Goncalves, A.; Dalenc, F.; Patsouris, A.; Ferrero, J.-M.; Levy, C.; Vanlemmens, L.; Lefeuvre, C.; Mathoulin-Pélissier, S.; Petit, T.; Courtinard, C.; Cailliot, C.; Pérol, D. Evolution of Overall Survival According to Year of Diagnosis (2008-2014) and Subtypes, among 16703 Metastatic Breast Cancer (MBC) Patients Included in the Real-Life “ESME” Cohort. *Journal of Clinical Oncology* **2017**, 35 (15_suppl), 1078. https://doi.org/10.1200/JCO.2017.35.15_suppl.1078.
- (21) Herceg, Z.; Wang, Z.-Q. Functions of Poly(ADP-Ribose) Polymerase (PARP) in DNA Repair, Genomic Integrity and Cell Death. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis* **2001**, 477 (1), 97–110. [https://doi.org/https://doi.org/10.1016/S0027-5107\(01\)00111-7](https://doi.org/https://doi.org/10.1016/S0027-5107(01)00111-7).
- (22) Isabelle, M.; Moreel, X.; Gagné, J.-P.; Rouleau, M.; Ethier, C.; Gagné, P.; Hendzel, M. J.; Poirier, G. G. Investigation of PARP-1, PARP-2, and PARG Interactomes by Affinity-Purification Mass Spectrometry. *Proteome Sci* **2010**, 8 (1), 22. <https://doi.org/10.1186/1477-5956-8-22>.
- (23) Cortesi, L.; Rugo, H. S.; Jackisch, C. An Overview of PARP Inhibitors for the Treatment of Breast Cancer. *Target Oncol* **2021**, 16 (3), 255–282. <https://doi.org/10.1007/s11523-021-00796-4>.

- (24) Singh, D. D.; Parveen, A.; Yadav, D. K. Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance. *Biomedicines* **2021**, *9* (11), 1512. <https://doi.org/10.3390/biomedicines9111512>.
- (25) Zheng, F.; Zhang, Y.; Chen, S.; Weng, X.; Rao, Y.; Fang, H. Mechanism and Current Progress of Poly ADP-Ribose Polymerase (PARP) Inhibitors in the Treatment of Ovarian Cancer. *Biomedicine & Pharmacotherapy* **2020**, *123*, 109661. <https://doi.org/https://doi.org/10.1016/j.biopha.2019.109661>.
- (26) Mateo, J.; Lord, C. J.; Serra, V.; Tutt, A.; Balmaña, J.; Castroviejo-Bermejo, M.; Cruz, C.; Oaknin, A.; Kaye, S. B.; de Bono, J. S. A Decade of Clinical Development of PARP Inhibitors in Perspective. *Ann Oncol* **2019**, *30* (9), 1437–1447. <https://doi.org/10.1093/annonc/mdz192>.
- (27) Saleh, L.; Wilson, C.; Holen, I. CDK4/6 Inhibitors: A Potential Therapeutic Approach for Triple Negative Breast Cancer. *MedComm (Beijing)* **2021**, *2* (4), 514–530. <https://doi.org/https://doi.org/10.1002/mco2.97>.
- (28) Hu, Y.; Gao, J.; Wang, M.; Li, M. Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer. *Cancer Manag Res* **2021**, *13*, 5223–5237. <https://doi.org/10.2147/CMAR.S310649>.
- (29) Cho, Y. S.; Angove, H.; Brain, C.; Chen, C. H.-T.; Cheng, H.; Cheng, R.; Chopra, R.; Chung, K.; Congreve, M.; Dagostin, C.; Davis, D. J.; Feltell, R.; Giraldez, J.; Hiscock, S. D.; Kim, S.; Kovats, S.; Lagu, B.; Lewry, K.; Loo, A.; Lu, Y.; Luzzio, M.; Maniara, W.; McMenamin, R.; Mortenson, P. N.; Benning, R.; O'Reilly, M.; Rees, D. C.; Shen, J.; Smith, T.; Wang, Y.; Williams, G.; Woolford, A. J.-A.; Wrona, W.; Xu, M.; Yang, F.; Howard, S. Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors. *ACS Med Chem Lett* **2012**, *3* (6), 445–449. <https://doi.org/10.1021/ml200241a>.
- (30) Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular Endothelial Growth Factor (VEGF) and Its Receptors. *The FASEB Journal* **1999**, *13*, 22–29.
- (31) Guo, S.; Colbert, L. S.; Fuller, M.; Zhang, Y.; Gonzalez-Perez, R. R. Vascular Endothelial Growth Factor Receptor-2 in Breast Cancer. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer* **2010**, *1806* (1), 108–121. <https://doi.org/https://doi.org/10.1016/j.bbcan.2010.04.004>.

- (32) Inai, T.; Mancuso, M.; Hashizume, H.; Baffert, F.; Haskell, A.; Baluk, P.; Hu-Lowe, D. D.; Shalinsky, D. R.; Thurston, G.; Yancopoulos, G. D.; McDonald, D. M. Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts. *Am J Pathol* **2004**, *165* (1), 35–52. [https://doi.org/10.1016/S0002-9440\(10\)63273-7](https://doi.org/10.1016/S0002-9440(10)63273-7).
- (33) Dent, S. F. The Role of VEGF in Triple-Negative Breast Cancer: Where Do We Go from Here? *Annals of Oncology* **2009**, *20* (10), 1615–1617. <https://doi.org/10.1093/annonc/mdp410>.
- (34) Sarrió, D.; Rodríguez-Pinilla, S. M.; Hardisson, D.; Cano, A.; Moreno-Bueno, G.; Palacios, J. Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype. *Cancer Res* **2008**, *68* (4), 989–997.
- (35) Hynes, N. E.; MacDonald, G. ErbB Receptors and Signaling Pathways in Cancer. *Curr Opin Cell Biol* **2009**, *21* (2), 177–184. <https://doi.org/https://doi.org/10.1016/j.ceb.2008.12.010>.
- (36) Yarden, Y.; Sliwkowski, M. X. Untangling the ErbB Signalling Network. *Nat Rev Mol Cell Biol* **2001**, *2* (2), 127–137.
- (37) Nakai, K.; Hung, M.-C.; Yamaguchi, H. A Perspective on Anti-EGFR Therapies Targeting Triple-Negative Breast Cancer. *Am J Cancer Res* **2016**, *6* (8), 1609–1623.
- (38) Maron, S. B.; Xu, J.; Janjigian, Y. Y. Targeting EGFR in Esophagogastric Cancer. *Front Oncol* **2020**, *10*.
- (39) Bhateja, P.; Cherian, M.; Majumder, S.; Ramaswamy, B. The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer? *Cancers (Basel)* **2019**, *11* (8), 1126. <https://doi.org/10.3390/cancers11081126>.
- (40) Zitvogel, L.; Kepp, O.; Galluzzi, L.; Kroemer, G. Inflammasomes in Carcinogenesis and Anticancer Immune Responses. *Nat Immunol* **2012**, *13* (4), 343–351. <https://doi.org/10.1038/ni.2224>.
- (41) Urbanelli, L.; Magini, A.; Buratta, S.; Brozzi, A.; Sagini, K.; Polchi, A.; Tancini, B.; Emiliani, C. Signaling Pathways in Exosomes Biogenesis, Secretion and Fate. *Genes (Basel)* **2013**, *4* (2), 152–170. <https://doi.org/10.3390/genes4020152>.

- (42) Chen, H.; Yang, J.; Yang, Y.; Zhang, J.; Xu, Y.; Lu, X. The Natural Products and Extracts: Anti-Triple-Negative Breast Cancer in Vitro. *Chem Biodivers* **2021**, *18* (7), e2001047. <https://doi.org/https://doi.org/10.1002/cbdv.202001047>.
- (43) Ser, H.-L.; Palanisamy, U. D.; Yin, W.-F.; Abd Malek, S. N.; Chan, K.-G.; Goh, B.-H.; Lee, L.-H. Presence of Antioxidative Agent, Pyrrolo[1,2-a]Pyrazine-1,4-Dione, Hexahydro- in Newly Isolated Streptomyces Mangrovisoli Sp. Nov. *Front Microbiol* **2015**, *6*.
- (44) Zhang, H.; Dong, M.; Wang, H.; Crews, P. Secondary Metabolites from the Marine Sponge Genus Phyllospongia. *Mar Drugs* **2017**, *15* (1). <https://doi.org/10.3390/md15010012>.
- (45) Gupta, P.; Sharma, U.; Schulz, T. C.; McLean, A. B.; Robins, A. J.; West, L. M. Bicyclic C21 Terpenoids from the Marine Sponge Clathria Compressa. *J Nat Prod* **2012**, *75* (6), 1223–1227.
- (46) Chevallier, C.; Bugni, T. S.; Feng, X.; Harper, M. K.; Orendt, A. M.; Ireland, C. M. Tedanolide C: A Potent New 18-Membered-Ring Cytotoxic Macrolide Isolated from the Papua New Guinea Marine Sponge Ircinia Sp. *J Org Chem* **2006**, *71* (6), 2510–2513.
- (47) Abdelmohsen, U. R.; Cheng, C.; Reimer, A.; Kozjak-Pavlovic, V.; Ibrahim, A. K.; Rudel, T.; Hentschel, U.; Edrada-Ebel, R.; Ahmed, S. A. Antichlamydial Sterol from the Red Sea Sponge Callyspongia Aff. Implexa. *Planta Med* **2015**, *81* (05), 382–387.
- (48) He, Q.; Miao, S.; Ni, N.; Man, Y.; Gong, K. A Review of the Secondary Metabolites From the Marine Sponges of the Genus Aaptos. *Nat Prod Commun* **2020**, *15* (9), 1934578X20951439. <https://doi.org/10.1177/1934578X20951439>.
- (49) Bakhtra, D. D. A.; Suryani, R.; Yuni, G. R.; Handayani, D. Antimicrobial and Cytotoxic Activities Screening of Symbiotic Fungi Extract Isolated from Marine Sponge Xestospongia Testudinaria DD-01. *J Chem Pharm Sci* **2019**, *12* (2), 30–34.
- (50) Lipinski, C. A. Rule of Five in 2015 and beyond: Target and Ligand Structural Limitations, Ligand Chemistry Structure and Drug Discovery Project Decisions. *Adv Drug Deliv Rev* **2016**, *101*, 34–41. <https://doi.org/https://doi.org/10.1016/j.addr.2016.04.029>.

- (51) Vilar, S.; Cozza, G.; Moro, S. Medicinal Chemistry and the Molecular Operating Environment (MOE): Application of QSAR and Molecular Docking to Drug Discovery. *Curr Top Med Chem* **2008**, *8* (18), 1555–1572.
- (52) Morris, G. M.; Lim-Wilby, M. Molecular Docking. In *Molecular Modeling of Proteins*; Kukol, A., Ed.; Humana Press: Totowa, NJ, 2008; pp 365–382. https://doi.org/10.1007/978-1-59745-177-2_19.
- (53) Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. *J Comput Chem* **2009**, *30* (16), 2785–2791. <https://doi.org/https://doi.org/10.1002/jcc.21256>.
- (54) John, M.; Pintacuda, G.; Park, A. Y.; Dixon, N. E.; Otting, G. Structure Determination of Protein–Ligand Complexes by Transferred Paramagnetic Shifts. *J Am Chem Soc* **2006**, *128* (39), 12910–12916. <https://doi.org/10.1021/ja063584z>.
- (55) Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and Scoring in Virtual Screening for Drug Discovery: Methods and Applications. *Nat Rev Drug Discov* **2004**, *3* (11), 935–949. <https://doi.org/10.1038/nrd1549>.
- (56) Halgren, T. A. Identifying and Characterizing Binding Sites and Assessing Druggability. *J Chem Inf Model* **2009**, *49* (2), 377–389. <https://doi.org/10.1021/ci800324m>.
- (57) Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. *Nucleic Acids Res* **2000**, *28* (1), 235–242. <https://doi.org/10.1093/nar/28.1.235>.
- (58) Ma, X.; Chen, C.; Yang, J. Predictive Model of Blood-Brain Barrier Penetration of Organic Compounds. *Acta Pharmacol Sin* **2005**, *26* (4), 500–512. <https://doi.org/10.1111/j.1745-7254.2005.00068.x>.
- (59) Zhao, Y. H.; Le, J.; Abraham, M. H.; Hersey, A.; Eddershaw, P. J.; Luscombe, C. N.; Boutina, D.; Beck, G.; Sherborne, B.; Cooper, I.; Platts, J. A. Evaluation of Human Intestinal Absorption Data and Subsequent Derivation of a Quantitative Structure–Activity Relationship (QSAR) with the Abraham Descriptors. *J Pharm Sci* **2001**, *90* (6), 749–784. <https://doi.org/https://doi.org/10.1002/jps.1031>.
- (60) Yamashita, S.; Furubayashi, T.; Kataoka, M.; Sakane, T.; Sezaki, H.; Tokuda, H. Optimized Conditions for Prediction of Intestinal Drug Permeability Using Caco-2

- Cells. *European Journal of Pharmaceutical Sciences* **2000**, 10 (3), 195–204. [https://doi.org/https://doi.org/10.1016/S0928-0987\(00\)00076-2](https://doi.org/https://doi.org/10.1016/S0928-0987(00)00076-2).
- (61) Lestari, T. *Studi Interaksi Senyawa Turunan 1,3-Dibenzoiltiourea Sebagai Ribonukleotida Reduktase Inhibitor*, 2015; Vol. 7. www.pdb.org.
- (62) Dwi Agistia, D.; Purnomo, H.; Tegar, M.; Endro Nugroho, A. INTERACTION BETWEEN ACTIVE COMPOUNDS FROM Aegle Marmelos CORREA AS ANTI INFLAMMATION AGENT WITH COX-1 AND COX-2 RECEPTOR INTERAKSI SENYAWA AKTIF DARI Aegle Marmelos CORREA SEBAGAI ANTI INFLAMASI DENGAN RESEPTOR COX-1 DAN COX-2. *Traditional Medicine Journal* **2013**, 18 (2), 2013.
- (63) Obaji, E.; Maksimainen, M. M.; Galera-Prat, A.; Lehtiö, L. Activation of PARP2/ARTD2 by DNA Damage Induces Conformational Changes Relieving Enzyme Autoinhibition. *Nat Commun* **2021**, 12 (1), 3479. <https://doi.org/10.1038/s41467-021-23800-x>.
- (64) Yuki, H.; Tanaka, Y.; Hata, M.; Ishikawa, H.; Neya, S.; Hoshino, T. Implementation of π - π Interactions in Molecular Dynamics Simulation. *J Comput Chem* **2007**, 28 (6), 1091–1099. <https://doi.org/https://doi.org/10.1002/jcc.20557>.
- (65) Kim, K.; Friesner, R. A. Hydrogen Bonding between Amino Acid Backbone and Side Chain Analogues: A High-Level Ab Initio Study. *J Am Chem Soc* **1997**, 119 (52), 12952–12961. <https://doi.org/10.1021/ja971836d>.
- (66) Stapley, B. J.; Doig, A. J. Hydrogen Bonding Interactions between Glutamine and Asparagine in α -Helical Peptides¹¹ Edited by A. R. Fersht. *J Mol Biol* **1997**, 272 (3), 465–473. <https://doi.org/https://doi.org/10.1006/jmbi.1997.1262>.